Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization

Area of Science:

• Cardiovascular Surgery
• Immunology
• Pharmacology

Background:

• Ischemia-reperfusion injury is a significant complication in cardiovascular surgery.
• Neutrophil activation, mediated by complement component 5a (C5a), plays a key role in this injury.
• Targeting C5a may offer a therapeutic strategy to mitigate surgical myocardial damage.

Purpose of the Study:

• To evaluate the efficacy of a recombinant human C5a antagonist, CGS 32359, in reducing neutrophil activation and infarct size.
• To assess the impact of CGS 32359 on cardiac function following surgical revascularization in a porcine model.

Main Methods:

• Porcine neutrophils were activated with human C5a, and the inhibitory effect of CGS 32359 on superoxide production and adherence to coronary endothelium was measured.
• A porcine model of surgical revascularization involved 50 minutes of left anterior descending coronary artery occlusion followed by reperfusion.
• Animals received saline, mannitol-buffer vehicle, or CGS 32359 during the procedure, with infarct size and cardiac function assessed post-reperfusion.

Main Results:

• CGS 32359 dose-dependently inhibited C5a-induced neutrophil superoxide production and reduced neutrophil adherence to coronary endothelium.
• Infarct size was significantly reduced in the CGS 32359 group (18%) compared to saline (52%) and vehicle (60%) groups.
• Postischemic systolic shortening was improved with CGS 32359, and myeloperoxidase activity was lower, indicating reduced neutrophil accumulation.

Conclusions:

• The recombinant human C5a receptor antagonist CGS 32359 effectively inhibits neutrophil activation.
• CGS 32359 significantly reduces infarct size and improves cardiac function in a porcine model of surgical ischemia-reperfusion injury.
• CGS 32359 demonstrates potential as a therapeutic agent to mitigate myocardial damage after coronary occlusion.